Our aim

• Finding a use for existing advanced small molecules in the therapeutic treatment of atopic dermatitis, psoriasis, actinic keratosis, acne, and related dermatological diseases.
  • We are looking for compounds addressing a specific target or pathway in a selective manner with a scientific rationale that supports their use on one or more indications of interest
  • More specifically, Research compounds that have shown a good potency and an acceptable pharmacokinetic profile or Development compounds that have shown a good human safety profile

Our partners

• Universities
• Research Centers
• Start-ups
• Biotechs
• Pharmaceutical companies

world-wide with an interest in pharmaceutical R&D

You benefits

• Biological profiling of your small molecule on key dermatological assays in vitro and in vivo
• Opportunity for an eventual long-term collaboration with us beyond the initial project
• Your intellectual property rights are protected
  • No need to disclose the chemical structure of your compound
  • All data and results generated will be treated as strictly confidential and will only be used to decide about future collaboration options
  • You will be the owner of the results obtained
  • We expect you not to patent, register, or communicate to any third party the results we generated whilst we are collaborating
• A specific contact person to help you with any questions will be available at any tim

Collaboration process

• Submit your proposal
  • As an initial step, you should create an account in AlmirallShare Innovation platform, a secure tool to keep and manage your proposals
  • You can submit your proposal at any time
  • All the initial information provided under the proposal should be non-confidential. Please do not reveal the chemical structure of your compound, even if it is published
  • Please include an outline of your proposal (max. 300 words) and a detailed description of your advanced compound properties, including at least biological data such as target and affinities (IC₅₀, Ki…etc), and available ADME data
• Proposal evaluation
  • A team of Almirall scientific experts will evaluate your proposal
  • The evaluation process will have a duration of 4-6 weeks after proposal submission
• Proposal selection
  • After the evaluation period, you will receive Almirall’s decision regarding the progression of your proposal
• Collaboration starts
  • If your proposal has been selected, we will help you to draft a Material Transfer Agreement (MTA)
  • Compounds will be tested in a pre-agreed panel of relevant cellular assays and in vivo disease models within a period of 4-6 months, starting upon MTA signature. This panel could be complemented with other assays, such as physicochemical properties and pharmacokinetic studies